Metabolic Features in Plasma and Urine of Obese Children and Their Association with MAFLD Risk

Why It Matters

The findings provide non‑invasive metabolic markers that can improve early diagnosis and enable sex‑tailored interventions for pediatric MAFLD, a condition affecting up to half of obese children.

Key Takeaways

• Alanine and proline in plasma increase MAFLD risk in obese children
• Hippuric acid and palmitic acid in urine lower MAFLD risk
• Alanine risk seen mainly in obese boys; palmitic acid protective in girls
• Dose‑response relationships for all four metabolites are linear
• Metabolite signatures offer potential non‑invasive biomarkers for pediatric MAFLD

Pulse Analysis

Pediatric metabolic dysfunction‑associated fatty liver disease (MAFLD) has surged alongside childhood obesity, now affecting roughly 13 % of all children and up to 47 % of those who are obese. Early identification is hampered by reliance on imaging and invasive liver biopsies, prompting a search for reliable, non‑invasive biomarkers. Metabolomic profiling—analyzing small‑molecule signatures in biofluids—offers a promising avenue, leveraging advances in liquid chromatography‑mass spectrometry to detect subtle biochemical shifts before overt disease manifests.

In a recent cross‑sectional study of 160 obese children, researchers employed untargeted LC‑MS/MS and GC‑MS to compare plasma and urine metabolites between those with MAFLD and those without. Four metabolites stood out: plasma alanine and proline correlated with increased disease risk, while urinary hippuric acid and palmitic acid were inversely associated. Notably, the risk linked to alanine was pronounced in boys, whereas the protective effect of palmitic acid was significant in girls, underscoring a clear sex dimorphism. Restricted cubic spline analyses revealed linear dose‑response curves for all four markers, reinforcing their potential as quantitative risk predictors.

The clinical implications are substantial. Incorporating these metabolites into routine screening could enable pediatricians to flag high‑risk patients using a simple urine or blood test, reducing dependence on costly imaging. Moreover, the sex‑specific insights pave the way for precision interventions—dietary or pharmacologic strategies tailored to boys or girls. Future research should validate these biomarkers in larger, ethnically diverse cohorts and explore mechanistic pathways, potentially unlocking new therapeutic targets for a disease that currently lacks approved pediatric treatments.